-Transformative Transaction Creates Premier Specialty Pharma
Company with a Broad Product Portfolio-
-Canadian Domicile Provides Compelling Platform for Growth with
Competitive Structure-
-US$350 Million Capital Commitment
from Deerfield-Led Syndicate-
MILTON, Ontario, Feb. 5, 2016 /PRNewswire/ -- Aralez
Pharmaceuticals Inc. ("Aralez") today announced the completion
of the business combination of POZEN Inc. ("POZEN") and
Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval
of the transaction by stockholders of POZEN and shareholders of
Tribute. The combined company will operate under Aralez
Pharmaceuticals Inc. ("Aralez"), a global specialty pharmaceutical
company with operations in Canada,
Ireland and the United States. Under the terms of the
Agreement and Plan of Merger and Arrangement, each share of POZEN
common stock has been converted into the right to receive one
Aralez common share and each common share of Tribute (other than
dissenting shares) has been exchanged for 0.1455 Aralez common
shares.
As of closing, Aralez has approximately 75 million outstanding
shares on a fully diluted basis. Commencing on or about
February 8, 2016, Aralez will trade
on NASDAQ under the ticker symbol "ARLZ", and on or about
February 10, 2016 will begin trading
on the Toronto Stock Exchange ("TSX") under the ticker symbol
"ARZ".
"As Aralez, we have established an efficient platform that
offers competitive advantages with committed capital to enable us
to aggressively build out our portfolio through strategic business
development and M&A, from which we plan to drive long-term
value creation for shareholders," said Adrian Adams, Chief Executive Officer of Aralez.
"We have a lean, nimble and performance-oriented operating business
model that will allow us to build value organically and through
accretive transactions and as such we believe that Aralez is well
positioned for further transformational growth."
About Aralez Pharmaceuticals Inc.
Aralez
Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global
specialty pharmaceutical company focused on delivering meaningful
products to improve patients' lives while focusing on creating
shareholder value by acquiring, developing and commercializing
products primarily in cardiovascular, pain and other specialty
areas. Aralez's Global Headquarters is in Ontario, Canada, the US Headquarters is
planned to be in Princeton, NJ and
the Irish Headquarters is in Dublin,
Ireland. More information about Aralez can be found at
www.aralez.com.
Cautionary Language Concerning Forward-Looking
Statements
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995:
This press release contains forward-looking statements under
applicable securities laws, including, but not limited to,
statements related to the proposed listing of Aralez on NASDAQ and
TSX and other statements that are not historical facts. These
forward-looking statements are based on Aralez's current
assumptions and expectations and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to
the combined company meeting the listing requirements on NASDAQ and
TSX and those risks relating to the transaction and the
combined business of POZEN, Tribute and Aralez detailed from
time-to-time under the caption "Risk Factors" and elsewhere in each
company's respective filings and reports with the SEC. The parties
undertake no duty or obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or changes in their expectations.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Contact Information:
Aralez Pharmaceuticals Inc.
Nichol
Ochsner
Executive Director,
Investor Relations & Corporate Communications
732.754.2545
nochsner@aralez.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pozen-and-tribute-combine-to-create-aralez-pharmaceuticals-inc-300216066.html
SOURCE Aralez Pharmaceuticals Inc.; POZEN Inc.; Tribute
Pharmaceuticals Canada Inc.